Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKD NASDAQ:PMD NASDAQ:PRE NASDAQ:VLON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$10.33-0.9%$12.60$5.70▼$22.90$20.32M0.9326,199 shs5,251 shsPMDPsychemedics$2.67$2.52$1.63▼$3.25N/AN/AN/A113,627 shsPREPrenetics Global$8.00-0.9%$8.33$3.09▼$11.99$103.88M0.1544,737 shs72,770 shsVLONVallon Pharmaceuticals$1.32+3.1%$0.67$0.21▼$12.92$17.80M-1.145.78 million shs280,906 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%-10.10%-15.95%-37.20%+1,032,999,900.00%PMDPsychemedics0.00%0.00%0.00%0.00%+17.12%PREPrenetics Global0.00%-0.74%-0.44%+51.80%+45.99%VLONVallon Pharmaceuticals+3.13%-33.67%-8.97%-37.14%+67.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVKDCadrenal Therapeutics2.1475 of 5 stars3.53.00.00.00.61.70.6PMDPsychemedicsN/AN/AN/AN/AN/AN/AN/AN/APREPrenetics Global2.5564 of 5 stars2.55.00.00.03.40.01.3VLONVallon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 3.00Buy$32.00209.78% UpsidePMDPsychemedics 0.00N/AN/AN/APREPrenetics Global 3.00Buy$9.0012.50% UpsideVLONVallon Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PMD, PRE, CVKD, and VLON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CVKDCadrenal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/APMDPsychemedics$19.68M0.83N/AN/A$0.84 per share3.18PREPrenetics Global$30.62M3.39N/AN/A$13.20 per share0.61VLONVallon Pharmaceuticals$100K177.96N/AN/A$0.18 per share7.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$10.65M-$9.26N/AN/AN/AN/A-244.94%-181.94%8/6/2025 (Estimated)PMDPsychemedics-$1.86M-$0.51N/A∞N/A-9.26%-32.32%-18.53%N/APREPrenetics Global-$46.30M-$3.99N/AN/AN/A-115.91%-28.07%-22.27%10/6/2025 (Estimated)VLONVallon Pharmaceuticals-$7.02M-$0.78N/A∞N/AN/A-230.48%-124.89%N/ALatest PMD, PRE, CVKD, and VLON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CVKDCadrenal Therapeutics-$1.60N/AN/AN/AN/AN/A6/12/2025Q1 2025PREPrenetics GlobalN/A-$0.80N/A-$0.80N/A$17.31 million5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/APMDPsychemedicsN/AN/AN/AN/A1 YearsPREPrenetics GlobalN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A4.324.32PMDPsychemedics0.011.821.82PREPrenetics GlobalN/A2.071.89VLONVallon PharmaceuticalsN/A2.292.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%PMDPsychemedics32.07%PREPrenetics Global25.01%VLONVallon Pharmaceuticals8.74%Insider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics48.62%PMDPsychemedics13.96%PREPrenetics Global7.80%VLONVallon Pharmaceuticals37.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics41.97 million1.01 millionNot OptionablePMDPsychemedics1406.11 million5.26 millionNot OptionablePREPrenetics Global112.98 million11.97 millionNot OptionableVLONVallon Pharmaceuticals313.48 million8.45 millionNot OptionablePMD, PRE, CVKD, and VLON HeadlinesRecent News About These CompaniesQuestcor Pharmaceuticals,July 21, 2023 | forbes.comVallon Pharmaceuticals' shareholders approve reverse merger with California companyApril 20, 2023 | bizjournals.comVallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock SplitApril 20, 2023 | finance.yahoo.comVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023April 12, 2023 | finance.yahoo.comLab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for mergerApril 7, 2023 | bizjournals.comVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETApril 4, 2023 | finance.yahoo.comVallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | finanznachrichten.deVallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | finance.yahoo.comIs Vallon Pharmaceuticals Inc (VLON) recent surge justifiedFebruary 14, 2023 | benzinga.comVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch EventJanuary 11, 2023 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLONDecember 27, 2022 | benzinga.comVallon rockets as it announces merger with GRI BioDecember 15, 2022 | thepharmaletter.comTSay goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on NasdaqDecember 14, 2022 | endpts.comEVallon Pharmaceuticals to merge with California biotech firm in 'best path forward'December 14, 2022 | bizjournals.comWhat's Going On With Vallon Pharmaceuticals Stock Today?December 14, 2022 | msn.comWhy Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving PremarketDecember 14, 2022 | benzinga.comVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell RegulatorsDecember 13, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateJuly 28, 2022 | finance.yahoo.comVallon Pharmaceuticals, Inc. (VLON)July 19, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Wall Street Is Betting on These 3 Comeback StocksBy Nathan Reiff | July 12, 2025View Why Wall Street Is Betting on These 3 Comeback StocksThis Drone Stock Is on Sale Despite Big Army ContractBy Jeffrey Neal Johnson | July 31, 2025View This Drone Stock Is on Sale Despite Big Army ContractJoby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?By Jeffrey Neal Johnson | July 14, 2025View Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?CrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins?By Chris Markoch | July 11, 2025View CrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins?Is Amazon Really the Best Forever Stock for Your Portfolio?By Sam Quirke | July 17, 2025View Is Amazon Really the Best Forever Stock for Your Portfolio?PMD, PRE, CVKD, and VLON Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$10.33 -0.09 (-0.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.35 +0.02 (+0.19%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Psychemedics NASDAQ:PMDPsychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.Prenetics Global NASDAQ:PRE$8.00 -0.07 (-0.87%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$7.91 -0.09 (-1.13%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.Vallon Pharmaceuticals NASDAQ:VLONVallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
